<table>
<thead>
<tr>
<th>Sr. No</th>
<th>Published</th>
<th>Title</th>
<th>Journal</th>
</tr>
</thead>
</table>
| 1.     | Phase 3 Human Clinical Trial  
https://doi.org/10.1101/2021.06.30.21259439 | Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a double-blind, randomised, controlled phase 3 trial | medRxiv               |
| 2.     | Phase 2 Human Clinical Trial  
https://doi.org/10.1016/S1473-3099(21)00070-0 | Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report | THE LANCET Infectious Diseases |
| 3.     | Phase 1 Human Clinical Trial  
https://doi.org/10.1016/S1473-3099(20)30942-7 | Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial | THE LANCET Infectious Diseases |
| 4.     | Neutralization of UK Variant (B.1.1.7)  
https://doi.org/10.1093/jtm/taab051 | Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2 | Clinical Infectious Diseases |
| 5.     | Neutralization of Double mutant (B.1.617)  
https://doi.org/10.1093/cid/ciab411 | Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees | Clinical Infectious Diseases |
| 6.     | Neutralization of Brazil variant of concern P2 (B.1.1.28)  
https://doi.org/10.1093/jtm/taab077 | Neutralization of B.1.1.28 P2 variant with sera of natural SARS-CoV-2 infection and recipients of BBV152 vaccine | Journal of Travel Medicine |
| 7.     | Neutralization of South Africa Variant (B.1.351) and Delta Variant (B.1.617.2)  
https://doi.org/10.1101/2021.06.05.447177 | Neutralization against B.1.351 and B.1.617.2 with sera of COVID-19 recovered cases and vaccinees of BBV152 | bioRxiv                |
| 8.     | Hamster Efficacy Study  
| 9.     | Non-Human Primate Efficacy Study  
https://doi.org/10.1038/s41467-021-21639-w | Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques | nature communications  |
| 10.    | Preclinical Safety and Immunogenicity  